Skip to content

Carbon Dioxide Acupulse Laser Treatment Versus Sham Treatment and Stress Urinary Incontinence Symptoms

Randomized, Double-blind, Sham-controlled Clinical Trial for Evaluating the Efficacy of Fractional Carbon Dioxide Laser in the Treatment of Stress Urinary Incontinence

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05097456
Enrollment
125
Registered
2021-10-28
Start date
2020-03-01
Completion date
2021-12-31
Last updated
2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress Urinary Incontinence

Brief summary

The study is intended to assess the safety and efficacy of Carbon dioxide AcuPulse laser treatment in patients with stress urinary incontinence. Eligible subjects will be randomized to either receive 3 laser or 3 sham treatment sessions, 4 weeks apart and 3 follow up visits 3, 6 and 12 months following the last treatment.

Detailed description

Following a screening visit, eligible subjects will be enrolled into the study. Subjects will be randomized into either laser treatment or sham treatment. Each subject will receive 3 treatments 4 weeks apart and 3 follow up visits, at 3, 6 and 12 months following the last treatment. Further demographic information and patient history will be obtained from the subjects' electronic files.

Interventions

carbon dioxide laser

DEVICEsham laser

sham laser

Sponsors

Rambam Health Care Campus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Negative urine analysis. * Normal Pap smear test from the recent 3 years. * No previous gynecological laser treatments. * Able and willing to comply with the treatment/follow-up schedule and requirements.

Exclusion criteria

* Active genital infection. * Subject presenting abnormal Pap result from the last three years. * Recurring urinary tract infection or recurring infection of genital herpes or candida (\> 2 episodes in the recent year). * Transvaginal mesh implant. * Serious systemic disease or any chronic condition that could interfere with study compliance. * Any vaginal bleeding of unknown reason.

Design outcomes

Primary

MeasureTime frameDescription
Pad weight testFrom treatment up to 12 months post treatmentChange in pad weight

Secondary

MeasureTime frameDescription
Cough testFrom treatment up to 12 months post treatmentPositive cough test
Urinary distress index questionnaireFrom treatment up to 12 months post treatmentChange in urinary distress index questionnaire scores
International consultation on incontinence questionnaire-urinary incontinenceFrom treatment up to 12 months post treatmentChange in international consultation on incontinence questionnaire-urinary incontinence scores
Pelvic organ prolapse/urinary incontinence sexual questionnaireFrom treatment up to 12 months post treatmentChange in pelvic organ prolapse/urinary incontinence sexual questionnaire scores

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026